Filing Flows › Gyre Therapeutics (GYRE) › Q1 2025
Gyre Therapeutics (GYRE) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 9, 2025
Gyre Therapeutics (GYRE) reported revenue of $22.1M for the first quarter 2025 (Q1 2025), -19% from a year earlier and -21% from the quarter before. Operating margin was 10.3%, net earnings $3.7M (16.9% of revenue).
Gyre Therapeutics, Q1 2025: revenue $22.1M (-19% year over year), operating margin 10.3%, net earnings $3.7M, operating cash flow −$129K. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $22.1M | -21% | -19% |
| Gross profit | $21.2M | -21% | -19% |
| Operating profit | $2.3M | +242% | -72% |
| Net earnings | $3.7M | +556% | -62% |
| Operating cash flow | −$129K | — | — |
What changed
Revenue was $22.1M in Q1 2025, down 19% year over year and down 21% from the previous quarter.
Gross margin was 95.9%, down 0.4 points from a year earlier. Operating profit was $2.3M, a 10.3% margin (down 19.4 points year over year). Operating expenses grew 4% against a revenue fall of 19%. The fastest-growing cost line was General & admin (+46%). Net earnings were $3.7M, down 62% year over year. The effective tax rate was 19.4%. Non-operating items added $2.4M, 51% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$129K. Non-cash charges added back $535K of depreciation and amortization and $507K of share-based compensation. Working capital and other items used $4.9M. Capital expenditures of $122K exceeded it, leaving free cash flow of −$251K.
Questions
What was Gyre Therapeutics' revenue in the first quarter 2025?
Gyre Therapeutics (GYRE) reported revenue of $22.1M for the first quarter 2025 (Q1 2025), -19% from a year earlier and -21% from the quarter before.
Was Gyre Therapeutics profitable in the first quarter 2025?
Operating profit was $2.3M (10.3% of revenue) and net earnings $3.7M.
Source: Gyre Therapeutics 10-Q on SEC EDGAR.